<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02030301</url>
  </required_header>
  <id_info>
    <org_study_id>HSV2-101</org_study_id>
    <nct_id>NCT02030301</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and effectiveness of two experimental
      therapeutic vaccines against herpes simplex virus, type 2 (HSV-2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose escalation study to evaluate the safety, immunogenicity, and efficacy of 3
      doses of HSV plasmid DNA (pDNA) vaccines formulated with Vaxfectin® in subjects with a
      minimum of 1 year of reported history of genital herpes, and either 2 to 9 recurrences within
      the year prior to screening, or 2 to 9 recurrences per year prior to starting suppressive
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to Day 420</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral shedding rate change from baseline</measure>
    <time_frame>Baseline, Day 150</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genital lesion rate change from baseline</measure>
    <time_frame>Baseline, Day 150</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HSV DNA copy numbers change from baseline</measure>
    <time_frame>Baseline, Day 150</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genital recurrence rate compared with placebo</measure>
    <time_frame>Up to Day 330</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subclinical genital shedding rate change from baseline</measure>
    <time_frame>Up to Day 150</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell and/or antibody responses change from baseline</measure>
    <time_frame>Baseline, Days 7, 35, 63, 150, 330</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Genital shedding rate change from baseline over time</measure>
    <time_frame>Baseline, Day 330</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Genital lesion rate change from baseline</measure>
    <time_frame>Baseline, Day 330</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Subclinical genital shedding rate change from baseline</measure>
    <time_frame>Baseline, Day 330</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Genital Herpes Simplex Type 2</condition>
  <arm_group>
    <arm_group_label>VCL-HB01, 0.25-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS, 0.25-mL dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VCL-HB01, 0.5-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS, 0.5-mL dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VCL-HB01, 1-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VCL-HM01, 1-mL dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS, 1-mL dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VCL-HB01</intervention_name>
    <description>Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®</description>
    <arm_group_label>VCL-HB01, 0.25-mL dose</arm_group_label>
    <arm_group_label>VCL-HB01, 0.5-mL dose</arm_group_label>
    <arm_group_label>VCL-HB01, 1-mL dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VCL-HM01</intervention_name>
    <description>Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®</description>
    <arm_group_label>VCL-HM01, 1-mL dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PBS</intervention_name>
    <description>Phosphate-buffered saline</description>
    <arm_group_label>PBS, 0.25-mL dose</arm_group_label>
    <arm_group_label>PBS, 0.5-mL dose</arm_group_label>
    <arm_group_label>PBS, 1-mL dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HSV-2 seropositive

          -  A minimum of 1 year of reported history of genital herpes and either 2 to 9
             recurrences within the year prior to screening or 2 to 9 recurrences per year prior to
             starting suppressive therapy

        Exclusion Criteria:

          -  History of receiving an investigational HSV vaccine

          -  Chronic illness for which a subject's immune system is suspected to be impaired or
             altered, such as cancer, autoimmune conditions, or diabetes

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mammen P. Mammen, Jr., MD,FACP,FIDSA</last_name>
    <role>Study Director</role>
    <affiliation>Vical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Vaccine Research Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Infectious Diseases Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westover Heights Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah - Division of Infectious Diseases</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes Simplex Virus, Type 2</keyword>
  <keyword>Herpes</keyword>
  <keyword>HSV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

